This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (46)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • General Rhinology  • Alert me on articles by topic  Social Bookmarking   What's this?

Valerie J. Lund, MD; Joanne Flood, RSN; Andrew P. Sykes, BSc; David H. Richards, BSc

Arch Otolaryngol Head Neck Surg. 1998;124:513-518.

Objectives  To investigate the effect of intranasal corticosteroids in the treatment of polyps in patients with severe polyposis listed for surgical treatment and to determine the treatment effect on the progression of the disease.

Design  A double-blind, randomized, parallel-group, placebo-controlled, 12-week study at a single center.

Setting  A tertiary referral center in London, England.

Patients  Thirty-four patients with severe polyposis listed for endoscopic surgical treatment.

Intervention  By random allocation, fluticasone propionate aqueous nasal spray (FPANS), 200 µg twice a day; beclomethasone dipropionate aqueous nasal spray, 200 µg twice a day; or placebo nasal spray twice a day was administered. Patients received 2 actuations to each nostril in the morning and in the evening.

Main Outcome Measures  Efficacy end points were the need for polypectomy at the end of treatment, the results of acoustic rhinometry, the polyp score, the peak nasal inspiratory flow rate, and an assessment of symptoms.

Results  The polyp score was significantly decreased in the FPANS-treated group (P.01). The nasal cavity volume was significantly increased in both the FPANS-treated group and the group receiving beclomethasone compared with placebo (P.01) at the end of treatment. The percentage change in the mean morning peak nasal inspiratory flow rate was greater in the FPANS-treated group, with a significant effect observed at week 2 (P=.01). Nasal blockage was significantly decreased in both active groups compared with the group receiving placebo. No significant difference was observed between the treatment groups in the number of patients requiring polypectomy.

Conclusions  Fluticasone and beclomethasone aqueous nasal sprays are effective in treating the symptoms of severe nasal polyps. There was some evidence that the group treated with FPANS responded more quickly to intervention and that the magnitude of the response was greater than in the group receiving beclomethasone.

From the Institute of Laryngology and Otology, Royal National Throat, Nose and Ear Hospital, London (Dr Lund and Ms Flood); Glaxo Wellcome Ltd, Greenford (Mr Sykes); and Glaxo Wellcome Research and Development Public Limited Company, Uxbridge, Middlesex (Mr Richards), England.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Use of Mometasone Furoate to Prevent Polyp Relapse After Endoscopic Sinus Surgery
Stjarne et al.
Arch Otolaryngol Head Neck Surg 2009;135:296-302.
ABSTRACT | FULL TEXT  

A randomized controlled trial of mometasone furoate nasal spray for the treatment of nasal polyposis.
Stjarne et al.
Arch Otolaryngol Head Neck Surg 2006;132:179-185.
ABSTRACT | FULL TEXT  

Intranasal steroids decrease eosinophils but not mucin expression in nasal polyps
Burgel et al.
Eur Respir J 2004;24:594-600.
ABSTRACT | FULL TEXT